Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need

Blood (2025) 146 (Supplement 1): 2756.

https://doi.org/10.1182/blood-2025-2756

Published: 2025

Journal Articles

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

William Johnson, Joseph Rocco, Rikita Patel, Adrianna Herskovits, Elena Mead, Jae Park, Alison Moskowitz, Zachary Epstein-Peterson, Robert Stuver, Neil Bapodra, Rabeya Molla, Andrew Intlekofer, Jennifer Lue, Lia Palomba, Ariela Noy, Jasmine Zain, Colette Owens, Lynnette Henshaw, Paola Ghione, Efrat Luttwak, Pallawi Torka, Andrew Zelenetz, Philip Caron, Anita Kumar, Lorenzo Falchi, Natasha Galasso, Paul Hamlin, Alexander Boardman, Kevin David, Raphael Steiner, Nivetha Ganesan, Tiffany Chang, Zainab Shahid, Wenbin Xiao, Annamaria Ballweg, Alina Markova, Mark Geyer, Lauren Banaszak, Roni Shouval, Sergio Giralt, Gregory Goldgof, Jodi Mones, Jeffrey Zwicker, Rekha Parameswaran, Avi Leader, Cy R. Wilkins, Simon Mantha, Jeffrey Cohen, Jessica Durkee-Shock, Matthew Sedlock, Bita Shakoory, Irini Sereti, Miguel-Angel Perales, Gilles Salles, Santosha Vardhana, Joseph Oved, Steven Horwitz

Blood (2025) 146 (Supplement 1): 2996.

https://doi.org/10.1182/blood-2025-2996

Published: 2025

Journal Articles

Transformed Waldenström macroglobulinemia is associated with poor outcomes and chemorefractory disease

Blood (2025) 146 (Supplement 1): 3573.

https://doi.org/10.1182/blood-2025-3573

Published: 2025

Journal Articles

Combined mosunetuzumab and zanubrutinib for the treatment of patients with newly diagnosed high-burden follicular lymphoma: First results of the multicenter phase 2 mithic-FL2 trial

Blood (2025) 146 (Supplement 1): 463.

https://doi.org/10.1182/blood-2025-463

Published: 2025

Journal Articles

Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 3691.

https://doi.org/10.1182/blood-2025-3691

Published: 2025

Journal Articles

Integrated dissociated and spatial single-cell profiling reveals that HDAC inhibition restores anti-PD-1 sensitivity in Hodgkin lymphoma by disrupting monocyte-Hodgkin-reed-sternberg cell-driven immunosuppressive niches.

Blood (2025) 146 (Supplement 1): 150.

https://doi.org/10.1182/blood-2025-150

Published: 2025

Journal Articles

Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study

Blood (2025) 146 (Supplement 1): 3605.

https://doi.org/10.1182/blood-2025-3605

Published: 2025

Journal Articles

A Phase II multicenter study of minimal residual disease-guided, time-limited acalabrutinib + obinutuzumab for the initial treatment of chronic lymphocytic leukemia

Blood (2025) 146 (Supplement 1): 5676.

https://doi.org/10.1182/blood-2025-5676

Published: 2025

Journal Articles

Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial

Blood (2025) 146 (Supplement 1): 1971.

https://doi.org/10.1182/blood-2025-1971

Published: 2025

Journal Articles

Improving outcomes with nivolumab consolidation among older patients (≥65) with previously untreated primary CNS lymphoma

Steven Park, Lakshmi Nayak, Danielle Boselli, Raphael Steiner, Christopher Jensen, Ashley Sumrall, Dai Chihara, Xhevahire Begic, Sarah Norek, Nazanin Majd, Chris Dittus

Blood (2025) 146 (Supplement 1): 1968.

https://doi.org/10.1182/blood-2025-1968

Published: 2025

Journal Articles

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

Blood (2025) 146 (Supplement 1): 5341.

https://doi.org/10.1182/blood-2025-5341

Published: 2025

Journal Articles

MSK-impact heme accurately reproduces diffuse large B-cell (DLBCL) dlbclass cluster classification across clinical scenarios, including diagnosis, relapse, and histological transformation

Blood (2025) 146 (Supplement 1): 1766.

https://doi.org/10.1182/blood-2025-1766

Published: 2025

Journal Articles

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 477.

https://doi.org/10.1182/blood-2025-477

Published: 2025

Journal Articles

Insights in the management of older adults with mantle cell lymphoma amidst a changing therapeutic landscape: Lessons from a 25-year institutional experience

Blood (2025) 146 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2025-1811

Published: 2025

Journal Articles

Are all GELF criteria created equal? utility of individual GELF criteria as guidance for treatment initiation in patients with advanced stage FL

Blood (2025) 146 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2025-1008

Published: 2025

Journal Articles

Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial

Blood (2024) 144 (Supplement 1): 340.

https://doi.org/10.1182/blood-2024-205046

Published: 2024

Journal Articles

Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma

Raphael Steiner, Liana Nikolaenko, Swetha Kambhampati, Niloufer Khan, Ranjit Nair, Jeremy S. Abramson, Steven Horwitz, Matthew Matasar, Colette Owens, Ildefonso Ismael Rodriguez Rivera, David J. Straus, Timothy S Pardee, Sanjeev Luther, Win Su Thet, Shreya Vemuri, Ariela Noy

Blood (2024) 144 (Supplement 1): 1729.

https://doi.org/10.1182/blood-2024-202459

Published: 2024

Journal Articles

Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis

Blood (2024) 144 (Supplement 1): 4485.

https://doi.org/10.1182/blood-2024-205803

Published: 2024

Journal Articles

CTEP 10590, NORM: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab

Raphael Steiner, Allison M. Bock, Alex F. Herrera, Omer Zulfa, Marc Hoffmann, Sami Ibrahimi, Natalie Galanina, Hun Ju Lee, Michael Green, Ruitao Lin, Chelsea C. Pinnix, Alison Moskowitz, Joachim Yahalom, Dai Chihara

Blood (2024) 144 (Supplement 1): 4434.2.

https://doi.org/10.1182/blood-2024-202516

Published: 2024

Journal Articles

Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin

Blood (2024) 144 (Supplement 1): 569.

https://doi.org/10.1182/blood-2024-202537

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Outcomes of patients (Pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) progressing after CD3xCD20 bispecific antibody (BsAb) therapy: A new unmet need

CXCL9 is a predictive biomarker of survival with IFNγ-targeted therapy in adult HLH patients

Transformed Waldenström macroglobulinemia is associated with poor outcomes and chemorefractory disease

Combined mosunetuzumab and zanubrutinib for the treatment of patients with newly diagnosed high-burden follicular lymphoma: First results of the multicenter phase 2 mithic-FL2 trial

Long-term clinical outcomes from the smart start trial: Rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma

Integrated dissociated and spatial single-cell profiling reveals that HDAC inhibition restores anti-PD-1 sensitivity in Hodgkin lymphoma by disrupting monocyte-Hodgkin-reed-sternberg cell-driven immunosuppressive niches.

Does increased PET avidity predict follicular lymphoma transformation? evidence from a large observational study

A Phase II multicenter study of minimal residual disease-guided, time-limited acalabrutinib + obinutuzumab for the initial treatment of chronic lymphocytic leukemia

Epcoritamab with lenalidomide and tafasitamab in patients with relapsed/refractory diffuse large B cell lymphoma (ECLAT), a phase 2 investigator-initiated trial

Improving outcomes with nivolumab consolidation among older patients (≥65) with previously untreated primary CNS lymphoma

Detection of intratumoral microorganisms in DLBCL impacts on CART-cell outcomes

MSK-impact heme accurately reproduces diffuse large B-cell (DLBCL) dlbclass cluster classification across clinical scenarios, including diagnosis, relapse, and histological transformation

primary analysis of the smart stop trial: Lenalidomide, tafasitamab, rituximab, and acalabrutinib alone and with combination chemotherapy in newly diagnosed diffuse large B-cell lymphoma

Insights in the management of older adults with mantle cell lymphoma amidst a changing therapeutic landscape: Lessons from a 25-year institutional experience

Are all GELF criteria created equal? utility of individual GELF criteria as guidance for treatment initiation in patients with advanced stage FL

Single-Agent Mosunetuzumab Produces High Complete Response Rates in Patients with Newly Diagnosed Follicular Lymphoma: Primary Analysis of the Mithic-FL1 Trial

Devimistat Results in a Low Complete Remission Rate in Heavily Pre-Treated Burkitt Lymphoma

Sequential R-CHOP/(R)-ICE and Dose-Adjusted EPOCH-R Are Both Appropriate Frontline Treatments for Newly Diagnosed Primary Mediastinal B-Cell Lymphoma: Results of a Retrospective Analysis

CTEP 10590, NORM: Nodular Lymphocyte Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase II Trial with Either Rituximab or Mosunetuzumab

Pembrolizumab Maintenance Instead of Autologous Hematopoietic Cell Transplantation for Patients with Relapsed or Refractory Hodgkin Lymphoma in Complete Response after Pembrolizumab, Gemcitabine, Vinorelbine, and Liposomal Doxorubicin

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only